[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622823":3},{"organization":4,"outcomesModule":7,"designInfo":51,"detailedDescription":20,"studyPopulation":54,"armGroups":20,"interventions":20,"overallOfficials":55,"centralContacts":60,"locations":70,"responsibleParty":93,"collaborators":20,"id":95,"slug":20,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":96,"sex":102,"minAge":103,"maxAge":20,"enrollmentInfo":104,"targetDuration":107,"studyType":108,"phases":20,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":73,"whyStopped":20,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Artcline GmbH","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":20},[9,13,15,18,21,24,26,28,30,32,34,37,40,43,46,49],{"measure":10,"description":11,"timeFrame":12},"Change in SOFA score D0 to SOFA Score D7 (or after last ARTICE® treatment, if later as D7).","SOFA Score is the Sequential Organ Failure Score providing information about mortality risk, 6 organs or organ systems are assesed using specific parameters, both the sum of the points and the point development of the individual organs can be considered, normal function of organ\u002Forgan system has 0 points, severely impacted function do have 4 point, in total you can have 0 points (every organ\u002Forgan system is normale) as a minimum and 24 points as maximum (severely impacted organ\u002Forgan system)","From enrollment up to 7 days after last ARTICE® treatment.",{"measure":14,"description":11,"timeFrame":12},"Changes in general SOFA score and SOFA sub scores.",{"measure":16,"description":17,"timeFrame":12},"Changes in standard lab and inflammatory biomarkers.","standard lab and inflammatory biomarkers for exampample are: ferritine, total bilirubin, kreatinine, CRP, lactate, gammaglobuline, amount of the different blodd cell types, like neutrophils, lymphocytes",{"measure":19,"description":20,"timeFrame":12},"Hospital survival rates.",null,{"measure":22,"description":23,"timeFrame":12},"Apache II Score.","APACHE II is a clinical rating system for evaluating the severity of an illness and the risk of death in intensive care medicine; score includes information on the patient's current condition, age and concomitant diseases, values are collected over 24 hours, highest value is included in calcutaion; the score can be at minimum 0 points (lightly risk of death) and at maximum 71 (very high risk of death)",{"measure":25,"description":20,"timeFrame":12},"Length of ICU stay (days).",{"measure":27,"description":20,"timeFrame":12},"Mechanical ventilation days.",{"measure":29,"description":20,"timeFrame":12},"Renal replacement therapy days.",{"measure":31,"description":20,"timeFrame":12},"Vasopressor therapy days.",{"measure":33,"description":20,"timeFrame":12},"Frequency of secondary infections.",{"measure":35,"description":36,"timeFrame":12},"Type of secondary infections: it will be divided into viral, bacterial or fungi infection.","It is recorded whether the infection is viral, bacterial, or caused by fungi. And in case of bacterial infection it will be recorded weather, it is gram-positive or gram-negative bacterial infection.",{"measure":38,"description":39,"timeFrame":12},"Changes in the physiological parameter heartrate.","as physiological parameter will be measured heartrate in bpm",{"measure":41,"description":42,"timeFrame":12},"Changes in physiological parameter blood pressure.","as physiological parameter will be measured systolic and diastolic blood pressure in mmHg.",{"measure":44,"description":45,"timeFrame":12},"Changes in physiological parameter body temperature.","as physiological parameter will be measured body temperature in °C",{"measure":47,"description":48,"timeFrame":12},"Changes in physiological parameter mean arterial pressure.","as physiological parameter will be measured mean arterial pressure in mmHG",{"measure":50,"description":20,"timeFrame":12},"Complications related to the ARTICE® therapy application.",{"allocation":20,"interventionModel":20,"interventionModelDescription":20,"primaryPurpose":20,"observationalModel":52,"timePerspective":53,"maskingInfo":20},"COHORT","PROSPECTIVE","Subjects ≥ 18 years who are planned to receive ARTICE® treatment during their ICU stay",[56],{"name":57,"affiliation":58,"role":59},"Martin Sauer, Prof. Dr. med.","Klinikum Magdeburg, Klinik für Intensiv- & Rettungsmedizin","PRINCIPAL_INVESTIGATOR",[61,66],{"name":62,"role":63,"phone":64,"phoneExt":20,"email":65},"Jens Altrichter, Dr. med.","CONTACT","+49 381 440 703 0","jens.altrichter@artcline.de",{"name":67,"role":63,"phone":68,"phoneExt":20,"email":69},"Judith Gross, M. Sc.","+49 1772216033","judith.gross@artcline.de",[71],{"facility":72,"status":73,"city":74,"state":20,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin","RECRUITING","Magdeburg","39130","Germany","DE",{"type":79,"coordinates":80},"Point",[81,82],11.63189,52.13129,{"lat":82,"lon":81},[85,90],{"name":86,"role":63,"phone":87,"phoneExt":88,"email":89},"Martin Sauer, Pof. Dr.","+49391791","3105","martin.sauer@klinikum-magdeburg.de",{"name":91,"role":63,"phone":87,"phoneExt":88,"email":92},"Georg Richter","georg.richter@Klinikum-Magdeburg.de",{"type":94,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100622823",false,"NCT07388628","ARTICE® Real Data Collection & Observational Trial, Phase 4 Study","ARTISTRY - ARTICE® Therapy Registry Study","ARTistry","Inclusion Criteria:\n\n* Subjects ≥ 18 years who are planned to receive ARTICE® treatment during their ICU stay\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":105,"type":106},200,"ESTIMATED","7 Days","OBSERVATIONAL","The objectives of this registry study are to:\n\n1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects.\n2. Further evaluate ARTICE® treatment efficacy.\n3. Identify potential sub-groups, assess their risk-benefit- and safety profile.\n4. Changes in SOFA score D0 to SOFA Score D7.",[111,112,113],"Sepsis","Septic Shock","Immunoparalysis in Septic Shock",[111,115,113],"septic shock","2026-02-06",{"date":118,"type":119},"2026-02-09","ACTUAL",{"date":121,"type":119},"2025-09-25",{"date":123,"type":106},"2027-12",{"name":5,"class":6},1]